within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AB09_Butaperazine;
model Butaperazine 
   extends Pharmacolibrary.Drugs.ATC.N.N05AB09;

  annotation(Documentation(
    info ="<html><body><p>Butaperazine is a typical antipsychotic drug belonging to the phenothiazine class; it was primarily used in the treatment of schizophrenia and other psychotic disorders. The drug is not widely used today, and it is not approved in most countries.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies specifically reporting PK parameters for butaperazine were identified. The following values are estimated based on general characteristics of phenothiazine antipsychotics in adults with normal renal and liver function.</p><h4>References</h4><ol><li><p>Cooper, TB, et al., &amp; Bergner, PE (1975). Butaperazine pharmacokinetics. Effect of dosage regimen on steady state blood levels. <i>Archives of general psychiatry</i> 32(7) 903–905. DOI:<a href=&quot;https://doi.org/10.1001/archpsyc.1975.01760250095010&quot;>10.1001/archpsyc.1975.01760250095010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/239664/&quot;>https://pubmed.ncbi.nlm.nih.gov/239664</a></p></li><li><p>Davis, JM, et al., &amp; el-Yousef, MK (1974). The pharmacokinetics of butaperazine in serum. <i>Advances in biochemical psychopharmacology</i> 9(0) 433–443. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4151767/&quot;>https://pubmed.ncbi.nlm.nih.gov/4151767</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Butaperazine;
